Aquestive Pharma (AQST): Price-to-Projected Revenue Ratio

Aquestive Therapeutics (AQST) - corporate logo

Tracking the forward P/S valuation history on GURU.Markets, we note that 10.20 serves as the current level of the metric for Aquestive Therapeutics (AQST). This trend reflects the company's ownership of exclusive patents for drug-films that generate steady income, alongside the growing prestige of the brand as an innovation leader. Robotic factories with AI control, which completely eliminate manual labor during production, further solidify the business efficiency.

AQST (aquestive.com) Forward P/S Multiple history from 07/04/2022 to 11/15/2026

Analytical breakdowns for Aquestive Therapeutics

- current price and projected stock value:
Stock Price Aquestive Therapeutics Inc|AQST - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Aquestive Therapeutics, Inc.|AQST - Full Takeover Company Value
- book value of equity indicators:
Accounting Value per Share Aquestive Therapeutics|AQST - Book Capitalization|Market Capitalization to Book Value Ratio aquestive.com|AQST - Company Assets
- debt and liquidity details:
Debt to Equity Aquestive Therapeutics|AQST - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Aquestive Therapeutics|AQST - Company Cumulative Indebtedness|Debts to Book Capitalization Aquestive Pharma|AQST - Long-Term Debt Volume|Company Current Liabilities Aquestive Therapeutics|Quick Ratio aquestive.com
- net income and valuation multiples indicators:
AQST - Company Net Income|Future Profit Aquestive Therapeutics|AQST - Company Value to Net Income|Projected Price to Earnings Aquestive Pharma|AQST - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Aquestive Therapeutics Inc|AQST - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Aquestive Therapeutics|AQST - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months aquestive.com|AQST - Earnings per share increase in current year|Earnings growth forecast for next year Aquestive Therapeutics
- total revenue and sales volume data:
AQST - Revenue and Sales Volume|Company Projected Revenue Aquestive Therapeutics, Inc.|AQST - Price-to-Sales Ratio|Forward P/S Multiple Aquestive Corp|AQST - Trailing Twelve Months Revenue Growth
General company analysis:Aquestive Corp AQST
Original product of aquestive.com

Aquestive Therapeutics (AQST) operates in the high-risk drug delivery systems segment. By analyzing the projected P/S trend, an investor assesses market capitalization dynamics relative to expected revenue. This forward-looking multiple measures the recovery speed of the business valuation and the market's level of confidence in future cash flows. For Aquestive Therapeutics (AQST), this is a critical indicator of resilience in the face of regulatory uncertainties and capital shortages before reaching break-even.

Analysis of competing companies

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|SCPH (scpharmaceuticals.com) - Forward P/S Multiple|TECX: Forward Price to Sales|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Forward Price to Sales BHST|Invizyne Technologies - Forward P/S Multiple|oramed.com (ORMP) - Forward Price-to-Revenue Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HYFT|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP